Etiracetam
Check on isomerdesign
Levetiracetam
Check on isomerdesign
Levetiracetam
Check on pubchem
Levetiracetam
Check on drugmap
Etiracetam
Check on wiki
Levetiracetam
Check on wiki
Data
InChI: InChI=1S/C8H14N2O2/c1-2-6(8(9)12)10-5-3-4-7(10)11/h6H,2-5H2,1H3,(H2,9,12)
Synonyms: LEVETIRACETAM [MI],(S)-2-(2-Oxo-1-pyrrolidinyl)butyramide,SR-01000759400,LEVETIRACETAM ACTAVIS GROUP, Levetiracetam In Sodium Chloride,ucb L059,(S)-Levetiracetam,Levetiracetamum,AB00639945-06,LEVETIRACETAM [VANDF],AC-1479,AKOS015841981,(S)-alpha-Ethyl-2-oxo-1-pyrrolidineacetamide, UCB-L 059,UCB 22059, ucb L060,SR-01000759400-4,Levetiracetam [USAN:USP:INN:BAN],LEVETIRACETAM [ORANGE BOOK],NCGC00186028-01, Levetiracetamum,MLS006010215,(2S)-2-(2-oxopyrrolidin-1-yl)butanamide;Levetiracetam,AM20070676,LEVETIRACETAM [USP-RS],BCP11856, Ucb L060,Levetiracetam actavis,E keppra (TN),MLS001424069,N03AX14, Etiracetam, S-isomer,HSDB 7528,HY-B0106,(S)-2-(2-oxopyrrolidin-1-yl)butyramide, UCB-22059,NSC760119,Levetiracetam- Bio-X,SCHEMBL118843, Levetriacetam, Levetiracetamum [INN-Latin],Keppra XR,matever,Levroxa,BL164623,Levetiracetam [INN],HMS2089L20,(S)-2-(2-Oxopyrrolidin-1-yl)butanamide,Levitiracetam, Pharmaceutical Secondary Standard; Certified Reference Material,UNII-44YRR34555,Levesam 500, Keppra,Levetiracetam,UCB-22059,(-)-(S)-alpha-ethyl-2-oxo-1-pyrrolidineacetamide (2S)-2-(2-Oxo-pyrrolidin-1-yl)butanamide,E Keppra,GTPL6826,AB00639945_08,Elepsia XR,Levetiracetam, >=98% (HPLC),HMS2051D07,Z1255435426,LEVETIRACETAM [MART.],HMS3713P16,(-)-(S)-.ALPHA.-ETHYL-2-OXO-1-PYRROLIDINEACETAMIDE,LEVETIRACETAM [EMA EPAR],D00709,Pharmakon1600-01502265,1-Pyrrolidineacetamide, alpha-ethyl-2-oxo-, (S)-, (-)-(S)-alpha-Ethyl-2-oxo-1-pyrrolidineacetamide,AB00639945_07,NSC-760119, (S)-2-(2-Oxopyrrolidin-1-yl)butanamide,MFCD03265610,(2S)-2-(2-oxopyrrolidin-1-yl)butanamide,Levetiracetam, United States Pharmacopeia (USP) Reference Standard,ACT02712,Levetiracetam (JAN/USP/INN),Levetiracetamum [INN-Latin],MLS000759403,LEVETIRACETAM RATIOPHARM,NC00178,NSC 760119, SIB-S1,Levetiracetam accord,Etiracetam levo-isomer,L-059,LEVETIRACETAM [HSDB], 44YRR34555,(S)-2-(2-OXO-PYRROLIDIN-1-YL)-BUTYRAMIDE, Levetiractam,LEVETIRACETAM [EP IMPURITY], Etiracetam levo-isomer,1-Pyrrolidineacetamide, alpha-ethyl-2-oxo-, (alphaS)-,STL388027,KS-1176,SDCCGSBI-0633760.P001,Tox21_500835,Levetiracetam In Sodium Chloride,Levetiracetam, European Pharmacopoeia (EP) Reference Standard,Elepsia, (2S)-2-(2-oxopyrrolidin-1-yl)butanamide,Levetiracetam, analytical standard,DB01202,SW197558-3,44YRR34555,CCG-100928, Levetiracetam [INN],Levetiracetam hospira,767L282, Keppra XR,LEVETIRACETAM [USP IMPURITY], 1-Pyrrolidineacetamide, alpha-ethyl-2-oxo-,,(s)-2-(2-oxopyrrolidin-1-yl) butyramide,Levetiracetam solution,102767-28-2,DTXSID9023207,Levipil,Levetiracetame,Leviteracetam,ZINC1547851,Keppra (TN),BIDD:GT0242,LP00835,(2S)-(2-Oxopyrrolidin-1-yl)butyramide, Keppra (TN),HMS3884O11, Levroxa,LEVETIRACETAM [EP MONOGRAPH],CHEMBL1286,LEVETIRACETAM [USAN],s1356,SMR000466303,NCGC00186028-13,Levetiracetam sun,CS-1854, (S)-alpha-Ethyl-2-oxo-1-pyrrolidineacetamide, 1-Pyrrolidineacetamide, alpha-ethyl-2-oxo-, (alphaS)-,LEVETIRACETAM [JAN],Keppra,BDBM50422542,UCB-L 059,ALBB-027275,UCB-L059,HMS3262H11,NCGC00261520-01,Torleva,LEVETIRACETAM [USP MONOGRAPH], ucb L059, Keppra, L-059, Leviteracetam,SIB-S1,Levetiracetam solution, 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material,C07841, CHEBI:6437, UCB-L059,AGB-101, Keppra, Keppra XR),Levetiracetam,(S)-(-)-alpha-ethyl-2-oxo-1-pyrrolidineacetamide,(-)-(S)-alpha-Ethyl-2-oxo-1-pyrrolidineacetamide,1-Pyrrolidineacetamide, .alpha.-ethyl-2-oxo-, (.alpha.S)-, Spritam,Levetiracetam 1.0 mg/ml in Methanol,EN300-244575,L0234, Torleva,Levetiracetam teva,A800616,Etiracetam, UNII-44YRR34555,CHEBI:6437,Q-201292,SR-01000759400-5,HMS2235I18,Spritam,LEVETIRACETAM [WHO-DD]
Estimated data
Solubility: -0.449 (log(S) in mol/L prediction using SolTranNet)
Blood Brain Barrier Permeability: Yes (prediction using frontiersin.org)
Addictivity Prediction: 47.8% (prediction based on www.mdpi.com)
